保留骨髓的 VMAT 在局部晚期宫颈癌同步放化疗女性中的动态免疫变化

Chemoradiotherapy is immunosuppressive in women with locally advanced cervical cancer (LACC). Both advanced external-beam radiation therapy (EBRT) and bone marrow sparing (BMS) radiotherapy techniques might lower bone marrow dose and therefore reduce the impact on the immune system. In this study, immune composition and function changes in the blood of women with LACC were evaluated for BMS volumetric-modulated arc therapy (VMAT) and exploratively compared with a historical cohort of women with LACC who underwent non-BMS radiotherapy (RT) with older EBRT techniques.

Women were treated with chemoradiotherapy followed by brachytherapy according to EMBRACE-II protocol (BMS VMAT) or with 46-52.5 Gy in 23-30 fractions (non-BMS RT). Blood samples for immunomonitoring were collected at set timepoints. Statistical analyses were performed using linear mixed-effects models.

Eighteen and eleven women received BMS VMAT and non-BMS RT, respectively. Although BMS VMAT reduced mean pelvic bone dose by 8.1 Gy, it did not prevent treatment-induced leukopenia and lymphopenia. Chemoradiotherapy mainly reduced CD4+ T helper cells and B cells, leaving CD8+ T-cell and natural killer-cell frequencies untouched. T-cell reactivity to common pathogens was decreased, despite sustained T-cell proliferative capacity, and coincided with increased numbers of regulatory T cells. The potential to activate immune cells remained intact, with small increases in dendritic cells, decreases in myeloid-derived suppressor cells, and preserved capacity of myeloid cells to present antigen and activate T cells.

Our study provided insight in the dynamic immune changes following chemoradiotherapy in LACC. As immunosuppression occurred with BMS VMAT, optimizing BMS and exploring other techniques is warranted.